"
Team:Penn/DrugDeliveryOverview
From 2012.igem.org
(Difference between revisions)
| Line 17: | Line 17: | ||
<tr> | <tr> | ||
<td width="500"> | <td width="500"> | ||
| - | <img src="https://static.igem.org/mediawiki/2012/f/fa/Spatial_Targeting.jpg" width=" | + | <img src="https://static.igem.org/mediawiki/2012/f/fa/Spatial_Targeting.jpg" width="450" height= "300" /> |
</td> | </td> | ||
<td> | <td> | ||
| - | <img src="https://static.igem.org/mediawiki/2012/6/6b/Cellular_Targeting.jpg" width = " | + | <img src="https://static.igem.org/mediawiki/2012/6/6b/Cellular_Targeting.jpg" width = "450" height = "300" /> |
</td> | </td> | ||
</tr> | </tr> | ||
Revision as of 23:47, 3 October 2012
Overview
Problems With Current Targeted Therapies
Current therapies generally rely on either spatial targeting (targeting within a physical area) or cellular targeting (targeting to a specific antigen or biomarker).
|
|
|
Spatial Targeting: Surgeons excise a tumor manually, without regard for cellular heterogeneity within and around the tunor area. |
Cellular Targeting: Monoclonal antibodies identify antigens on certain cells or viruses. Monoclonal antibodies are often coupled with therapeutic agents. However, if the antigen is present in healthy tissue outside the diseased area, it will be targeted as well. |
